CPHI Podcast Series: Saudi Arabia’s health sector transformation: can it advance the domestic manufacture of pharmaceuticals?
The Government of Saudi Arabia is seeking to expand the private sector’s role in providing healthcare services under its Vision 2030 and National Transformation Program. Some of these ambitious goals include plans to expand the privatization of government services, incorporate health IT and digital records, and increase the number of qualified Saudi nurses and licensed medical facilities.
In recent years, the government’s efforts to curb pharmaceuticals expenditure and promote local manufacturing have resulted in a fast-growing generics market. European, US, and Indian companies have established production facilities in the country – and in particular at the King Abdullah Economic Industrial Valley – providing a full range of products including antibiotics, diabetic treatments, cardiovascular drugs, and anticoagulants. So opportunities abound for additional manufacturers to establish a presence in the Kingdom, especially in vaccines, APIs, injectables, and biologics.
In this podcast interview, Musaed Alkholief, Associate Professor at the College of Pharmacy, King Saud University, and Consultant at King Abdullah Institute for Research and Consulting Studies discusses how biopharmaceutical companies can unlock those undoubted opportunities presented by the proposed transformation of Saudi Arabia’s health sector.
Related News
-
News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel
A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to... -
.png)
News Protecting life-saving therapies: CPHI Online Podcast Series
The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.
-
News 2026 Outsourcing Outlook Update - pharma at a crossroads
The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ... -
News Roche maintains German investment commitment whilst rivals scale back
Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.
-
News Women in Pharma: The History of CPHI Women in Japan
Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive. -
News EU drafts deal to end essential medicines shortage
European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.
-
News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg
The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th... -
News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026
CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.